Alkermes Public Limited Company (ALKS)

In the past six months, Alkermes Plc (ALKS) stock has been impacted by several key events. Alkermes announced an agreement to acquire Avadel Pharmaceuticals plc for up to $2.1 billion, which is expected to augment Alkermes' revenue growth and diversify its commercial portfolio. Alkermes reported strong financial performance, with its third-quarter 2025 earnings beating analyst estimates. Several equities research analysts have recently issued positive reports on Alkermes. Alkermes announced positive topline results from Vibrance-1, a Phase 2 study evaluating alixorexton for the treatment of narcolepsy type 1. On October 15, 2025, EVP Craig C. Hopkinson sold 9,000 shares of the company's stock.

Alkermes Plc's product sales exhibit demand seasonality. The company anticipates a sequential decrease in royalty and manufacturing revenue in the first quarter due to the annual reset of royalty tiers on long-acting INVEGA products, the conclusion of certain manufacturing revenue streams, and typical Q1 end-market seasonality. For its proprietary commercial product portfolio, Q1 net sales are expected to reflect wholesaler inventory normalization related to extra ordering in Q4, usual first-quarter inventory drawdown patterns, and typical Q1 patient copay and deductible reset dynamics, in addition to historical demand patterns.

Alkermes Plc is a global biopharmaceutical company focused on developing innovative medicines for central nervous system (CNS) disorders and oncology. The company's sector is Biotechnology, and its industry is Drug Manufacturers - Specialty & Generic. Alkermes has a diverse portfolio of proprietary commercial products, including Aristada for schizophrenia, Vivitrol for alcohol and opioid dependence, Lybalvi for schizophrenia and bipolar I disorder, and Vumerity for multiple sclerosis. The company also has other products utilizing its proprietary technologies, such as Risperdal Consta and Invega Sustenna, Invega Trinza, and Invega Hafyerain for schizophrenia and bipolar I disorder. In November 2023, Alkermes completed the separation of its oncology business into a new company, Mural Oncology.

Alkermes Plc has a global footprint, with its corporate headquarters located in Dublin, Ireland. Key operational, research and development (R&D), and manufacturing functions are distributed across strategic locations in the United States, specifically Waltham, Massachusetts, and Wilmington, Ohio. In May 2024, Alkermes completed the sale of its Athlone, Ireland facility to Novo Nordisk.

Alkermes Plc is recognized as an employer of choice in the life sciences industry. The company is committed to reducing its environmental impact and promoting sustainable practices.

Alkermes Plc has a significant institutional ownership. As of October 17, 2025, 837 institutional owners and shareholders held a total of 208,952,171 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Price T Rowe Associates Inc /md/, State Street Corp., Baker Bros. Advisors Lp., Renaissance Technologies Llc., Jpmorgan Chase & Co., and Rtw Investments, Lp. Institutional ownership accounts for approximately 89.59% of the shares, with individuals holding about 1.45%.